Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 85Recurrence 9Immunoglobulin Light-chain Amyloidosis 6Neoplasms, Plasma Cell 3Plasmacytoma 2Lymphoma 2Leukemia, Plasma Cell 2Hematologic Neoplasms 2Amyloidosis 2Smoldering Multiple Myeloma 1Proteostasis Deficiencies 1POEMS Syndrome 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1Genetic Diseases, Inborn 1Chromosome 17 deletion 1Alzheimer Disease 1

Interventions

Lenalidomide 11Dexamethasone 11fludarabine 9Cyclophosphamide 7Bortezomib 6fludarabine phosphate 5Melphalan 5pomalidomide 4isatuximab 3daratumumab 3Tacrolimus 3Mycophenolic Acid 3Busulfan 3dacetuzumab 2Whole-Body Irradiation 2Thiotepa 2Stem Cell Transplantation 2Leukapheresis 2KW-2478 2Granulocyte Colony-Stimulating Factor 2Cyclosporine 2Calcium Dobesilate 2tanespimycin 1spartalizumab 1sargramostim 1ricolinostat 1pirtobrutinib 1pembrolizumab 1nirogacestat 1ixazomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × ixazomib × Plasma cell × Clear all
NCT02440464 2023-01-04

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
57 enrolled 22 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡